At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 168 enrolled
Drug / intervention
Androderm®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV, Multi-center, Open-label, Single-arm 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Study of 16 Weeks Treatment With Androderm® in Hypogonadal Men
In Brief
A Phase 4 clinical trial evaluating Androderm® for Hypogonadism. Completed, enrolled 168 participants across 41 sites.
Detailed Summary
This study will evaluate the effect of a once daily Androderm® dose on Blood Pressure (BP) in adult hypogonadal men as measured by 24-hour ABPM.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypogonadism
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartMay 2020
Primary CompletionJun 2021
TodayJul 2026
First PostedMar 25, 2020
Enrollment StartMay 19, 2020
Primary CompletionJun 24, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 6.3 years ago
Interventions
Androderm®drug
Androderm® transdermal dose.